Introduction: Breast cancer (BC) is the most common malignant neoplasm among women, with a significant proportion of cases associated with genetic factors. Despite therapeutic advancements such as surgery and chemotherapy, challenges remain, including metastasis and treatment resistance. In this context, the Gail Model is used in clinical practice to estimate the risk of invasive breast cancer based on factors such as age, family history, and histological changes. Among the main hereditary genetic factors are mutations in the BRCA1 and BRCA2 genes, which can elevate the lifetime risk of the disease up to 80%. For women with these mutations, prophylactic measures such as risk-reducing mastectomy and bilateral salpingo-oophorectomy are recommended, typically after reproductive planning, with initiation between 35 to 40 years for BRCA1 and 40 to 45 years for BRCA2 mutations. This study evaluates the genetic impact on therapeutic choices for breast cancer in Pará, aiming at personalized strategies. Objective: To analyze the influence of genetic factors on therapeutic decisions related to BC through an epidemiological study based on the treatment profile of patients in the state of Pará. Method: This is an ecological, descriptive, and retrospective study based on breast cancer cases recorded in Pará between 2020 and 2024, using secondary data extracted from the Oncology Panel – DATASUS (Brazil). Variables such as therapeutic modality and patients’ age group were analyzed. Results: Between 2020 and 2024, there were 4,079 cases of BC in the state of Pará, of which 98.92% (n=4,035) were female, confirming the predominance of the disease among women. Of the total cases, 17.07% (n=697) were treated through surgical intervention, with 98.69% (n=688) in female patients. Some of these surgeries included risk-reducing procedures for women with genetic predisposition, even if not carriers of BRCA1/2 mutations, suggesting that other genetic markers have also influenced therapeutic decisions. Chemotherapy was the most commonly adopted modality, accounting for 68.32% (n=2,787) of recorded treatments, with 98.35% (n=2,769) in women. Radiotherapy accounted for 1.83% (n=75) of cases, with 97.33% (n=73) in female patients. Only 2 cases (both women) received combined treatment (surgery and radiotherapy). Additionally, 12.69% (n?874) of records did not specify the therapeutic modality, limiting a more in-depth analysis of clinical practices. The analysis of age revealed that 50.26% (n=189) of women undergoing surgery were in the 50–59 age group, and the 40–59 range accounted for 46.48% (n=324) of surgeries performed, indicating a higher frequency of surgical decisions in ages consistent with prophylactic recommendations for high-risk women. Conclusion: The data highlight the prevalence of BC among women in Pará, with chemotherapy and surgery as main treatments. The higher frequency of surgeries in women aged 40 to 59 suggests genetic influence on therapeutic decisions, emphasizing the importance of genetic screening and personalized approaches in treatment.
It is with great enthusiasm that we present the Annals of the Oncology International Symposium 2025, an event that continues to solidify its significance in the oncology landscape of northern Brazil. Held in Belém, Pará, Oncology 2025 centered around the theme "The cancer control challenge: better knowing it to best facing it," dedicating itself to exploring the latest frontiers in cancer treatment and prevention.
This year, the symposium provided a deep dive into the essential role of knowledge in the fight against cancer, presenting new perspectives and scientific advancements across various areas of oncology. Renowned global experts gathered to share their most recent research and innovative approaches, offering participants a comprehensive view of the challenges faced by healthcare professionals and patients worldwide.
Presentations and discussions during the event focused on critical topics such as the use of new technologies, advancements in personalized therapies, and more effective prevention strategies. Additionally, particular attention was given to the unique challenges faced by the Amazon region, with efforts aimed at developing region-specific solutions to meet local needs.
Beyond being a high-caliber academic event, Oncology 2025 stood out as a moment for integration and professional networking, with the warm hospitality of the city of Belém offering participants a unique experience. This event became a platform for exchanging ideas, where science, culture, and humanity came together in pursuit of a common goal: to improve cancer control both in Brazil and globally.
This collection of abstracts and articles presented during the event reflects the ongoing dedication to research and the development of innovative solutions, highlighting the importance of collaboration and shared knowledge in the fight against cancer.
General Submission Guidelines:
The presenting author, who does not have to be the first author, must be registered for Oncology 2025.
Each abstract may have up to 10 authors, including the main author and co-authors.
Only original, unpublished work will be accepted.
Submissions must be related to oncology. However, project descriptions, work proposals, experience reports, and literature reviews will not be considered.
Clinical case reports are allowed, provided the abstract addresses scientific questions, details clinical observations, and includes primary scientific data.
The abstract must be written in English, but presentations may be given in Portuguese.
Abstracts must be between 300 and 500 words.
Comissão Organizadora
Comissão Científica
See Annals of Oncology 2023 at:
https://www.even3.com.br/anais/oncology-2023-international-symposium/
Complete tool for submission, evaluation and publication of proceedings for scientific events.
